Induce Biologics
Induce Biologics commercializes a family of allograft bone graft bioimplants using its proprietary Natural Matrix Protein (NMP) technology, selling exclusively to verified spine, foot & ankle, and dental surgeons in the USA and Canada through distributors and a B2B e-commerce platform.
- Company typePrivate
- Founded2008
- HeadquartersToronto, Canada
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Induce Biologics does
Induce Biologics USA Inc., incorporated in Michigan and headquartered in Tampa, FL, is a privately held orthobiologics company commercializing a family of bone graft bioimplants based on its proprietary Natural Matrix Protein (NMP) technology. The NMP process demineralizes human allograft bone to unlock growth factors naturally embedded in the matrix - BMP-2, BMP-7, TGF-β1, VEGF, and PDGF - releasing them over a 10+ week window rather than the 1-2 day burst typical of recombinant BMP-2 products, with reported superior bone formation versus DBM and rhBMP-2 in animal studies and 89.1% CT-confirmed bridging bone in human ALIF procedures. The product line is organized across three surgical specialties: Ortho & Spine (NMP Fibers, Micro Particulates, Cancellous, Strips, and Particulates Crushed), Foot & Ankle (InduceXT), and Dental (Induce Oi-9 in FiberMatrix, Micro Particulates, and Cancellous forms).
The company sells exclusively to verified healthcare professionals and hospitals through a dual B2B model - an authenticated e-commerce platform on InduceBiologics.com plus an actively recruited independent distributor network spanning Spine, Foot & Ankle, and Dental channels - with direct surgeon engagement for high-value accounts. Pricing is quote-based and not publicly disclosed. Tissue sourcing and processing are executed through AATB-accredited tissue bank partners (Solvita/CTS-Dayton, PTT) with FDA Tissue Establishment Registrations, allowing NMP products to be regulated solely under Section 361 of the PHS Act as 361 HCT/P.
Commercial validation is being built through four registered ClinicalTrials.gov studies covering approximately 1,360 enrolled/planned patients, and the company quantifies 26-29% biologic cost reduction per case versus INFUSE and i-FACTOR, translating to over $270,000 in estimated annual savings per facility. Induce Biologics serves markets in the USA and Canada, operates with a micro headcount of 1-10 employees, and is led by a six-person executive team with deep prior tenures at the US Navy Tissue Bank, American Red Cross, GenSci, Bioventus, Alphatec, Zimmer, NAMSA, and Edwards Lifesciences.
Induce Biologics firmographics
Firmographics- Name
- Induce Biologics
- Legal name
- Induce Biologics USA Inc.
- Website
- https://inducebiologics.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Induce Biologics commercializes a family of allograft bone graft bioimplants using its proprietary Natural Matrix Protein (NMP) technology, selling exclusively to verified spine, foot & ankle, and dental surgeons in the USA and Canada through distributors and a B2B e-commerce platform.
- Ownership category
- akta.pro rank
Induce Biologics industry classification
Industry- Product category
- Orthobiologic Bone Graft Products
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)
- akta.pro secondary industry
- Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)
Keywords
Where Induce Biologics is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
Induce Biologics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Bioimplant Product Sales: Induce Biologics generates revenue through the sale of NMP bioimplant products including fibers, particulates, strips, FiberMatrix, and cancellous bone allograft products. These are tissue-based products sold to healthcare professionals for bone regeneration procedures in spine, foot & ankle, and dental surgeries.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Quote-based pricing for qualified healthcare professionals |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels5 records
Induce Biologics product offering
Product offeringCore offering
Induce Biologics develops, manufactures, and sells 100% allograft bone-graft bioimplants processed with its proprietary Natural Matrix Protein (NMP) technology. The product family includes NMP Fibers, Micro Particulates, Cancellous, Strips, and Particulates Crushed for spine applications; InduceXT for foot and ankle surgery; and the Induce Oi-9 FiberMatrix, Micro Particulates, and Cancellous line for dental bone regeneration. Products are sold to qualified healthcare professionals (spine surgeons, foot and ankle surgeons, dental surgeons) and healthcare facilities through independent distributors and a verified B2B online ordering platform.
Product overview
Induce Biologics commercializes a family of bioimplants featuring Natural Matrix Protein (NMP) proprietary technology for natural bone regeneration. The product portfolio spans three surgical specialties: Ortho & Spine (NMP Fibers, Micro Particulates, Cancellous, Strips, and Particulates Crushed), Foot & Ankle (InduceXT™), and Dental (INDUCE Oi-9™ product line including FiberMatrix, Micro Particulates, and Cancellous forms). All products are 100% allograft tissue-based bioimplants that are freeze-dried, sterile, and stored at ambient temperature. The NMP process unlocks growth factors naturally found in bone (including BMP-2, BMP-7, TGF-β1, VEGF, and PDGF), making them bioavailable for enhanced bone regeneration.
Differentiator
Problem solved
Functional benefit
Brands
- InduceXT: Advanced bone regeneration bioimplant using NMP technology, specifically developed for foot and ankle surgery. Contains multiple growth factors including BMP-2, BMP-7, TGF-ß1, VEGF, and PDGF.
- Induce Oi-9
- NMP
Products and services
- NMP Fibers (Long) Cortical fibers for spine and orthopedic bone grafting that are intertwined and curled with length greater than 25mm, available in sizes from 1.2cc (X Small) to 15.7cc (X Large). Produced with the proprietary NMP process that unlocks native growth factors including BMP-2, BMP-7, TGF-β1, VEGF, and PDGF for natural bone regeneration. Sold to qualified healthcare professionals and healthcare facilities performing spine fusion procedures.
- NMP Micro Particulates Cortical particulates for spine and orthopedic bone grafting ranging from 0.25mm to 1mm in size, available in XX Small (0.5cc), X Small (1.0cc), and Small (2.5cc) volumes. Produced with NMP technology and sold to qualified spine surgeons and healthcare facilities.
- NMP Cancellous Cancellous particulates for spine and orthopedic bone grafting, less than 4mm in size, available in X Small (1cc) through X Large (15cc). Produced with NMP technology and sold to qualified spine surgeons and healthcare facilities.
- NMP Strips Cancellous strips for spine and orthopedic bone grafting, available in Tall (10x10x15mm), Long (30x20x6mm), and X Long (48x20x6mm) configurations. Produced with NMP technology and sold to qualified spine surgeons and healthcare facilities.
- NMP Particulates Crushed Cancellous crushed particulates less than 4mm in size for bone void filling applications, produced with NMP technology and sold to qualified healthcare professionals.
- InduceXT Human allograft bioimplant containing multiple growth factors (BMP-2, BMP-7, TGF-β1, VEGF, and PDGF) processed with the proprietary NMP technology and specifically developed for foot and ankle surgery. Contains NMP fibers, NMP micro particulates, and mineralized cancellous bone; packable, withstands irrigation, shelf-stable with a 5-year shelf life, and rehydrates in 5-10 minutes. Sold to qualified foot and ankle surgeons and surgical facilities.
- Induce Oi-9 FiberMatrix Dental bioimplant composed of cortical fibers and cortical particulates for dental bone regeneration, processed with NMP technology. 100% allograft product available in 0.5cc, 1.0cc, and 2.5cc sizes. Sold to qualified dental surgeons performing socket preservation, dental implant placement, sinus lift, ridge augmentation, and maxillofacial reconstruction.
- Induce Oi-9 Micro Particulates Dental bioimplant with micro particulate form for dental bone regeneration, processed with NMP technology. 100% allograft product available in 0.5cc, 1.0cc, and 2.5cc sizes. Sold to qualified dental surgeons.
- Induce Oi-9 Cancellous Dental bioimplant with cancellous bone form for dental bone regeneration, processed with NMP technology. 100% allograft product available in 0.5cc, 1.0cc, and 2.5cc sizes. Sold to qualified dental surgeons.
Quantifiable outcome
- 89.1% CT-confirmed Grade 3A bridging bone at 12 months in ALIF procedures
- +4 more outcomes
Companies that use Induce Biologics
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles4 records
Induce Biologics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Induce Biologics partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- Solvita/CTS-DaytoncoreTissue bank partner accredited by AATB for donor screening, tissue procurement procedures, and processing of human bone using proprietary NMP process. Located in Dayton, Ohio.
- PTT (Tissue Establishment)coreTissue establishment partner with AATB accreditation and FDA tissue establishment registration for processing human bone using NMP proprietary process.
- American Association of Tissue Banks (AATB)coreAccreditation body that accredits tissue banks that partner with Induce Biologics for donor screening and tissue procurement. The company requires tissue bank partners to maintain AATB accreditation.
- Tissue Banks Accredited by AATBcoreNetwork of AATB-accredited tissue banks performing donor screening, tissue procurement procedures, and processing of human bone using proprietary NMP technology.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
Induce Biologics competitors and assessment
Company assessmentBroad incumbents
- Orthofix: Orthofix is a spine and orthopedic device company with a biologics portfolio including bone graft substitutes used in spine fusion. It competes with Induce in spine biologics distribution and hospital contracting.
- Medtronic (INFUSE Bone Graft): Medtronic's INFUSE (rhBMP-2) is the dominant recombinant growth factor bone graft product in spine and orthobiologics. Induce Biologics explicitly benchmarks against INFUSE on cost and clinical outcomes, positioning NMP as a competing alternative across spine, foot & ankle, and dental indications.
- Stryker: Stryker operates a broad orthopedic and spine portfolio including bone graft substitutes and orthobiologics. As a major medtech incumbent, it competes with Induce across hospital channels and benefits from deeper distribution and surgeon relationships.
- DePuy Synthes (Johnson & Johnson): DePuy Synthes offers a broad orthopedic, spine, and biologics portfolio including bone graft solutions. Induce's CCO has prior strategic partnership experience with DePuy, and the company competes across the same hospital and surgeon channels.
Direct peers
- Bioventus: Bioventus is a leading orthobiologics company offering bone graft and joint preservation products. Induce's CEO previously held senior leadership at Bioventus, and Bioventus competes in adjacent bone-healing and spine biologics categories.
- RTI Surgical: RTI Surgical is a tissue-based allograft and orthobiologics company serving spine, orthopedic, and dental surgeons. Its allograft-based bone graft portfolio directly competes with Induce's NMP allograft implants across overlapping specialties.
- MTF Biologics: MTF Biologics is one of the largest tissue banks and orthobiologics providers in the US, supplying allograft-based bone graft and sports medicine products. It is directly comparable to Induce on the allograft bone graft supply side and competitive portfolio overlap in spine and dental.
- SeaSpine: SeaSpine (now part of Globus Medical) specializes in spine fusion hardware and orthobiologics including DBM-based bone graft substitutes. It is a direct competitor to Induce in the spine surgery bone graft segment.
- NuTech Spine / NuTech Medical: NuTech Medical is a tissue-based allograft and orthobiologics company focused on spine and orthopedic procedures. Induce's CCO previously led sales at NuTech, and the company competes in adjacent allograft spine bone graft markets.
Regional players
- Alphatec Spine: Alphatec Spine is a spine-focused medical device company with an orthobiologics portfolio including bone graft solutions. Induce's CCO previously held sales leadership at Alphatec, making it a relevant former-employer comparable with overlapping spine distribution channels.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Induce Biologics social profiles
Digital presenceInduce Biologics compliance and trust
Trust signalCompliance8 records
Induce Biologics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Induce Biologics leadership team
Management profileNumber of profiles
Profiles7 records
Induce Biologics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Induce Biologics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Induce Biologics
What does Induce Biologics do?
Induce Biologics develops, manufactures, and sells 100% allograft bone-graft bioimplants processed with its proprietary Natural Matrix Protein (NMP) technology. The product family includes NMP Fibers, Micro Particulates, Cancellous, Strips, and Particulates Crushed for spine applications; InduceXT for foot and ankle surgery; and the Induce Oi-9 FiberMatrix, Micro Particulates, and Cancellous line for dental bone regeneration. Products are sold to qualified healthcare professionals (spine surgeons, foot and ankle surgeons, dental surgeons) and healthcare facilities through independent distributors and a verified B2B online ordering platform.
Is Induce Biologics a public or private company?
Induce Biologics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Induce Biologics founded?
Induce Biologics was founded in 2008. It employs 1 to 10 people.
Where is Induce Biologics based?
Induce Biologics is headquartered in Toronto, Canada, in the North America region.
How does Induce Biologics make money?
One revenue line is on record: bioimplant Product Sales.
Who are Induce Biologics's main competitors?
Broad incumbents on record are Orthofix, Medtronic (INFUSE Bone Graft), Stryker and DePuy Synthes (Johnson & Johnson). Direct peers are Bioventus, RTI Surgical, MTF Biologics, SeaSpine and NuTech Spine / NuTech Medical. Alphatec Spine is listed as a regional player.
Does Induce Biologics have an API?
No public API is recorded for Induce Biologics.
What industry is Induce Biologics in?
Induce Biologics's product category is Orthobiologic Bone Graft Products. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM), with a secondary code of HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration. Its NAICS code is 339113 and its SIC code is 3842.